ArticleFrontiers in pharmacology2012
Recurrent oral cancer: current and emerging therapeutic approaches.
Article in Frontiers in pharmacology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
71 citing papers in PubMed, 1 synthesis or guideline pooled it, 135 citations in OpenAlex.
- Portrait of DNA methylated genes predictive of poor prognosis in head and neck cancer and the implication for targeted therapy.Scientific reports · 2021Pooled it
- Sclareol Inhibit Cell Growth and Induces Apoptosis via Activation of p53/p21 Signaling Pathways in Human Oral Squamous Cell Carcinoma Cells.Journal of biochemical and molecular toxicology · 2026Article
- A Practical Method for Detecting Prognostic CD57+ T Cells in Head and Neck Cancer.Head & neck · 2026Article
- Exploring the GDP binding to KRasEuropean biophysics journal : EBJ · 2026Article
- Emerging Salivary Exosome Nanodiagnostics for Early Oral Squamous Cell Carcinoma: Platforms, Biomarkers, and Future Perspectives.International journal of nanomedicine · 2026Review
- Strategies in the development of pro-oxidant therapy for oral squamous cell carcinoma: A scoping review.Journal of Taibah University Medical Sciences · 2025Review
- Successful Treatment of Recurrent Unresectable Oral Cancer with Sequential Targeted Therapy, Surgery, and Metronomic Chemotherapy.South Asian journal of cancer · 2025Article
- Investigation of the Molecular Mechanisms of Paraoxonase-2 Mediated Radiotherapy and Chemotherapy Resistance in Oral Squamous Cell Carcinoma.Clinical and translational science · 2025Review
- Determinants of oral cavity cancer recurrence in Pakistan: findings from a cross-sectional study using an institutional cancer registry.BMC cancer · 2025Article
- E-Cigarette effects on oral health: A molecular perspective.Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association · 2025Review
- Combination Therapy of Curcumin and Cisplatin Encapsulated in Niosome Nanoparticles for Enhanced Oral Cancer Treatment.Indian journal of clinical biochemistry : IJCB · 2025Article
- Long-term oncologic outcomes and prognostic factors related to recurrences in pathologic Stage I/II early oral tongue cancer.Frontiers in surgery · 2025Article
- Factors associated with the survival of oral cavity cancer patients: a single institution experience from Karachi, Pakistan.BMC oral health · 2024Article
- Potential role of heteroplasmic mitochondrial DNA mutations in modulating the subtype-specific adaptation of oral squamous cell carcinoma to cisplatin therapy.Discover oncology · 2024Article
- Natural Prenylflavones from the Stem Bark ofACS omega · 2024Article
- Radiomic Biomarkers of Locoregional Recurrence: Prognostic Insights from Oral Cavity Squamous Cell Carcinoma preoperative CT scans.Research square · 2024Article
- Exposure to Secondhand Smoke Extract Increases Cisplatin Resistance in Head and Neck Cancer Cells.International journal of molecular sciences · 2024Article
- Radiomic biomarkers of locoregional recurrence: prognostic insights from oral cavity squamous cell carcinoma preoperative CT scans.Frontiers in oncology · 2024Article
- Volume-based 18F-fluorodeoxyglucose positron emission tomography/computed tomography parameters correlate with delayed neck metastasis in clinical early-stage oral squamous cell carcinoma.Oral radiology · 2023Article
- Redox-Sensitive Delivery of Doxorubicin from Nanoparticles of Poly(ethylene glycol)-Chitosan Copolymer for Treatment of Drug-Resistant Oral Cancer Cells.International journal of molecular sciences · 2023Article
11 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oral cavity cancer (OCC) is associated with high incidence of loco-regional recurrences, which account for the majority of treatment failures post-surgery and radiotherapy. The time-course of relapse manifestation and metastasis are unpredictable. Relapsed OCC represents a major clinical challenge in part due to their aggressive and invasive behaviors. Chemotherapy remains the only option for advanced OCC whenever salvage surgery or re-irradiation is not feasible, but its efficacy is limited as a result of the drug resistance development. Alternatives to use of different permutations of standard cytotoxic drugs or combinations with modulators of drug resistance have led to incremental therapeutic benefits. The introduction of targeted agents and biologics against selective targets that drive cancer progression has opened-up optimism to achieve superior therapeutic activity and overcome drug resistance because, unlike the non-selective cytotoxic, the target can be monitored at molecular levels to identify patients who can benefit from the drug. This review discusses the multifactorial aspects of clinical drug resistance and emerging therapeutic approaches in recurrent OCC, emphasizing recent advances in targeted therapies, immunotherapy, and potential relevance of new concepts such as epithelial-mesenchymal transition and cancer stem cell hypothesis to drug resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.